KRAS Inhibitors Market Heads Toward USD 9.2 Billion by 2032

KRAS Inhibitors Market Heads Toward USD 9.2 Billion as G12D, Broad RAS Targeting and First-Line Therapy Redefine Precision Oncology

The global KRAS inhibitors market is entering a new commercial phase as drug development moves beyond the first generation of G12C therapies toward G12D-selective drugs, broader RAS inhibitors, combination regimens and earlier-line treatment. According to the analysis, the market was valued at approximately USD 620 million in 2025 and is projected to reach around USD 9.2 billion by 2032, expanding at a CAGR of approximately 47.0% during 2026–2032.

The next wave of competition is being shaped less by whether KRAS can be targeted and more by how many mutation-defined patient groups each company can reach. The first commercial products established G12C as a viable oncology target, particularly in non-small cell lung cancer. That commercial base is now being supplemented by programs aimed at G12D, G12V and broader RAS-driven cancers, increasing the number of potential treatment settings across pancreatic, colorectal and lung cancers.

This shift matters because the mutation profile varies sharply by tumor type. KRAS alterations are found in approximately 90% of pancreatic adenocarcinomas, 44% of colon adenocarcinomas and 36% of lung adenocarcinomas based on NCI analysis of AACR GENIE data. The scale of these molecularly defined patient populations is pushing drug developers to build portfolios that go beyond a single mutation and a single indication.

Commercial momentum has already been established by first-generation G12C therapies. In 2025, Amgen reported USD 363 million in worldwide Lumakras/Lumykras sales, while Bristol Myers Squibb reported USD 205 million in Krazati sales. Together, the two products generated approximately USD 568 million, accounting for most of the disclosed commercial sales within the approved KRAS inhibitor class during the year.

However, the market is no longer being defined only by G12C NSCLC. Pancreatic cancer is becoming one of the most important areas for future commercial expansion because of its very high KRAS mutation burden and the concentration of G12D and G12V alterations. The approval of RASONQUE, or daraxonrasib, in August 2026 marked an important step by extending commercial RAS-targeted treatment beyond the original G12C model. The therapy was approved for adults with metastatic pancreatic adenocarcinoma who had received at least one previous systemic therapy or were unsuitable for multiagent systemic treatment.

The competitive focus is now moving toward first-line use. Revolution Medicines has advanced zoldonrasib into Phase III development for first-line RAS G12D metastatic pancreatic cancer, while daraxonrasib is also being evaluated in earlier treatment settings. First-line positioning is commercially significant because it increases the number of eligible patients and may extend treatment exposure before patients progress through several previous regimens.

G12D is expected to become one of the most closely watched segments of the market. It accounts for roughly one-third of KRAS mutations overall and has a particularly strong presence in pancreatic cancer. Astellas is developing setidegrasib, previously known as ASP3082, using a targeted protein degradation approach rather than conventional inhibition. The program entered Phase III development in April 2026, highlighting the increasing diversity of mechanisms being used to attack the same mutation-defined opportunity.

Competition is also intensifying within G12C. Roche reported positive Phase III results for divarasib in previously treated advanced NSCLC, while Eli Lilly is developing olomorasib in first-line settings in combination with pembrolizumab. These programs indicate that newer entrants are no longer competing only against chemotherapy. They are increasingly being measured against established targeted therapies, raising the importance of survival outcomes, tolerability, treatment duration and positioning within existing oncology pathways.

Combination treatment is becoming especially important in colorectal cancer. KRAS G12C accounts for only a small share of colorectal cases, which limits the standalone patient pool. The commercial strategy has therefore increasingly focused on combinations with EGFR inhibitors. Sotorasib plus panitumumab received U.S. approval for previously treated KRAS G12C-mutated metastatic colorectal cancer after demonstrating improved progression-free survival and response compared with standard therapy. Companion diagnostics are becoming part of the same commercial pathway because patients must first be identified by mutation status before targeted therapy can be prescribed.

Pricing and market access will remain important variables as the treatment population expands. High-value oncology therapies can generate significant commercial returns from relatively small patient populations, but actual market capture depends on reimbursement, treatment duration, net pricing and regional access. The difference between biological eligibility and commercially treated patients will therefore remain a central factor in future market modelling.

The competitive landscape is also moving toward platform-based strategies. Companies with assets spanning multiple mutations, tumor types and mechanisms may be better positioned than developers relying on one product. Revolution Medicines is building around broad RAS and G12D programs, Roche is seeking differentiation within G12C, Eli Lilly is targeting earlier-line treatment and Astellas is pursuing protein degradation. Bristol Myers Squibb’s acquisition of Mirati also reflects the strategic value of owning a broader precision-oncology portfolio rather than relying only on current product sales.

By 2032, the KRAS inhibitors market is expected to look substantially different from the market established by the first G12C launches. The leading competitive positions are likely to be determined by mutation coverage, entry into first-line therapy, strength in pancreatic cancer, combination strategies, genomic testing access and the ability to manage resistance. The companies that can convert these clinical advances into durable regulatory approvals and broad patient access are likely to shape the next stage of the RAS-targeted oncology market.